Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.
This table compares Zynerba Pharmaceuticals and Millendo Therapeutics’ revenue, earnings per share and valuation.
Millendo Therapeutics has higher revenue and earnings than Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than Millendo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional Insider Ownership
36.7% of Zynerba Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.5% of Millendo Therapeutics shares are owned by institutional investors. 10.8% of Zynerba Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Millendo Therapeutics